Approved & therapeutic
Glatiramer acetate
Copaxone, Glatopa
Glatiramer acetate is not a single peptide but a random synthetic polymer of four amino acids — L-glutamic acid, L-alanine, L-tyrosine and L-lysine — approved for relapsing forms of multiple sclerosis. Its composition is defined statistically rather than by a fixed sequence.
Also known as: Copaxone, Glatopa, copolymer 1, COP-1
- Status
- Glatiramer acetate is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Not meaningfully defined — the polymer is largely hydrolysed at the injection site and in local tissue, and intact drug is not measurably present in the systemic circulation.
- How it's taken
- Subcutaneous injection
- Mechanism
- Immune modulation
How Glatiramer acetate works
The mechanism is not fully established. The prevailing account is that glatiramer acetate acts as an altered peptide ligand resembling myelin basic protein, promoting a shift from pro-inflammatory Th1 to regulatory Th2 T-cell responses. These glatiramer-reactive Th2 cells are thought to cross the blood-brain barrier and exert bystander suppression of inflammation in the central nervous system. It also appears to influence antigen-presenting cell function.
What research has looked at
- Reduces relapse rate in relapsing-remitting multiple sclerosis; this was the basis of approval and has been reproduced across trials.
- It has one of the longest real-world safety records among disease-modifying therapies for MS, with over three decades of use.
- It is not associated with the infection or malignancy risks that accompany more potent immunosuppressive MS therapies, and requires no routine laboratory monitoring.
- Available in a daily and a three-times-weekly strength, with generic versions available.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Injection-site reactions are very common — pain, erythema, induration, pruritus — and lipoatrophy at injection sites can be permanent, making site rotation important.
- An immediate post-injection reaction of flushing, chest tightness, palpitations, anxiety and dyspnoea occurs in a substantial minority; it is transient and self-limiting but alarming, and can be mistaken for a cardiac event.
- Hepatic injury including rare cases of severe liver injury has been reported.
- Chest pain unrelated to the post-injection reaction is reported.
- It is not effective for primary progressive multiple sclerosis.
Sources
- FDA approved-drug listing for glatiramer acetate · U.S. Food & Drug Administration
- DailyMed prescribing information for glatiramer acetate · NIH · DailyMed
- PubMed research on glatiramer acetate multiple sclerosis · NIH · National Library of Medicine
- DrugBank record for glatiramer acetate · DrugBank
Track Glatiramer acetate in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Glatiramer acetate FAQ
What is Glatiramer acetate?
Glatiramer acetate is not a single peptide but a random synthetic polymer of four amino acids — L-glutamic acid, L-alanine, L-tyrosine and L-lysine — approved for relapsing forms of multiple sclerosis. Its composition is defined statistically rather than by a fixed sequence.
How does Glatiramer acetate work?
The mechanism is not fully established. The prevailing account is that glatiramer acetate acts as an altered peptide ligand resembling myelin basic protein, promoting a shift from pro-inflammatory Th1 to regulatory Th2 T-cell responses. These glatiramer-reactive Th2 cells are thought to cross the blood-brain barrier and exert bystander suppression of inflammation in the central nervous system. It also appears to influence antigen-presenting cell function.
Is Glatiramer acetate FDA approved?
Yes. Glatiramer acetate is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Glatiramer acetate?
Reported half-life: Not meaningfully defined — the polymer is largely hydrolysed at the injection site and in local tissue, and intact drug is not measurably present in the systemic circulation.
How is Glatiramer acetate taken?
Subcutaneous injection.
What side effects have been reported with Glatiramer acetate?
Reported in the sources: Injection-site reactions are very common — pain, erythema, induration, pruritus — and lipoatrophy at injection sites can be permanent, making site rotation important; An immediate post-injection reaction of flushing, chest tightness, palpitations, anxiety and dyspnoea occurs in a substantial minority; it is transient and self-limiting but alarming, and can be mistaken for a cardiac event; Hepatic injury including rare cases of severe liver injury has been reported; Chest pain unrelated to the post-injection reaction is reported; It is not effective for primary progressive multiple sclerosis.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.